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SUMMARY
An 87- year- old man with dementia with Lewy bodies, 
living in residential aged care, exhibited rapid functional 
decline and weight loss associated with injurious falls 
over 9 months. Independent clinicians (geriatrician 
and exercise physiologist) assessed him during an 
extended wait- list period prior to his commencement 
of a pilot exercise trial. The highly significant role of 
treatable factors including polypharmacy, sarcopenia 
and malnutrition as contributors to frailty and rapid 
functional decline in this patient are described. The 
results of a targeted intervention of deprescribing, robust 
exercise and increased caloric intake on his physical 
and neuropsychological health status are presented. 
This case highlights the need to aggressively identify 
and robustly treat reversible contributors to frailty, 
irrespective of advanced age, progressive ’untreatable’ 
neurodegenerative disease and rapidly deteriorating 
health in such individuals. Frailty is not a contraindication 
to robust exercise; it is, in fact, one of the most important 
reasons to prescribe it.
BACkgRoUnd
Frailty is a medical syndrome of increased depen-
dency, vulnerability to stressors and excess mortality 
that is driven by diminished strength, endurance, 
neuropsychological and physiological functions.1 
The prevalence of frailty increases with age and 
chronic disease burden. However, there are also 
significant reversible components to this syndrome 
that are critical to diagnose and treat specifically. 
Morley et al describe the aetiology of frailty as the 
interaction among four central factors: sarcopenia, 
malnutrition, atherosclerosis and cognitive impair-
ment.2 Extrinsic factors such as decreased physical 
activity and immobilisation, insufficient dietary 
energy and protein intake, texture- modified diets 
and the iatrogenic effects of medications may add 
to pathophysiologic stressors including cachexia 
from chronic disease, cardiac and skeletal muscle 
dysfunction, sedation, apathy, depression, lone-
liness, delirium, psychosis, anorexia of ageing, 
dysphagia, poor dentition, impairment of vision, 
smell and taste. All of these stressors exert pres-
sure on these four key components of frailty and 
are modifiable to a varying degree.2–10 Additionally, 
malnutrition, cognitive impairment and atheroscle-
rosis can all exacerbate sarcopenia by contributing 
to a negative energy balance, reduced drive to exer-
cise and a significant reduction in physical capacity, 
respectively.11
In the residential aged care environment, there 
is a confluence of these risk factors for frailty, 
resulting in a five- fold higher incidence than among 
community- dwelling older adults.12 13 Guidelines 
for aged care facilities traditionally focus on safety/
falls reduction,14 which is the leading cause of acci-
dental death in these facilities.15 Many recommen-
dations for falls reduction, such as deprescribing 
high- risk medications and offering challenging 
balance exercises, may improve frailty as well.14 
However, a safety focus can also lead to undesirable 
practices such as the use of restraints and immobil-
ising chairs, which may reduce falls risk but actively 
exacerbate underlying frailty; thereby leaving the 
individual even more vulnerable to injurious falls 
and adverse outcomes.16 Recently released guide-
lines on frailty clearly recommend anabolic inter-
ventions such as progressive resistance exercise and 
increased protein/energy intake as first- line treat-
ments to prevent and treat frailty.17 Evidence for 
the efficacy of this approach in frail populations 
has been available since the 1990s18 but has not 
yet become routine practice within residential aged 
care. The potential for remediating frailty is signif-
icant, especially for those living with dementia, 
who experience the highest levels of frailty in this 
setting.19 Notably, the aetiology of frailty in indi-
viduals with dementia is reported to have minimal 
correlation with the burden of disease pathology in 
the brain,20 suggesting that the higher incidence of 
frailty cannot be attributed to normal disease course 
and may be related to factors more amenable to 
intervention.
The following case provides a rare, longitu-
dinal insight into the aetiology and progression 
of frailty in a patient of advanced age with an 
aggressive neurodegenerative disease: dementia 
with Lewy bodies (DLB). We highlight the critical 
importance of differentiating disease progression 
from remediable causes of frailty, and the posi-
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Table 1 Investigations and patient timeline
Time point/event november 2016, initial assessment december 
2016





Review of systems Patient reports constant hunger, 
feelings of isolation and dizziness on 
standing. Negative for pain, depression, 
Cardiovascular symptoms or dyspnoea
Patient still reports constant 
hunger, and feelings of isolation 
increased. Negative for dizziness, 
pain, depression, CVD Sx or 
dyspnoea
Patient reports hunger, increased isolation. 
Negative for pain, troubling hallucinations, 
depression, CVD Sx or dyspnoea.
Clinical course and physical 
examination
Weight loss >5 kg in 12 months and 
reduced muscle bulk diffusely. Kyphotic 
posture c/w Hx of hip fracture (2012). 
Ecchymosis widespread, acute ankle 
sprain. Cerebellar ataxia w. standing and 
walking c/w Hx excessive alcohol use.
Sepsis and seizure following fall. 
Further weight loss of 6.5 kg 
in 2 months, diffuse wasting. 
Ecchymosis still present. Decreased 
alertness c/w delirium, gait 
stability and strength/function.
Further weight loss of 11 kg in 5 months 
and severe, diffuse wasting. Healed rib 
fracture secondary to fall, immobilised 
with restraints. Decreased alertness. 
Ecchymosis still present. Unable to stand. 
Tardive dyskinesia, trunk dystonia to 
the right side, increased limb rigidity. 


















120/50 mm Hg, 50 bpm
110/50 mm Hg, 62 bpm
108/48 mm Hg, 70 bpm
8.43 kgm−2
L—25 kg (45th percentile)






118/50 mm Hg, 56 bpm
126/60 mm Hg, 70 bpm
128/460 mm Hg, 68 bpm
7.8 kgm−2
L—20 kg (25th percentile)




57 kg / 17.7 kg/m2
Unable to perform due to immobility
 
N/A
L—17 kg (15th percentile)
R—17 kg (10th percentile
Pathology TC: 4.7 mmol/L, LDL: 2.5 mmol/L, Vit. D: 
58 nmol/L
No pathology results available for 
review by the research team
No pathology results available for review 
by the research team
Recommendations to facility 
doctor
Review need for aspirin, perindopril, 
atorvastatin, and mirtazapine.
Recommend vitamin D—1000 IU/day.
Flagged as high falls risk, malnourished 
and sarcopenic
Increase energy intake by 
an addition of high protein 
supplements and larger meal 
portions.
Review needs for aspirin
Discussed in the Intervention section
Implemented 
recommendations
Removal of perindopril and atorvastatin. 
Vitamin D was not added, aspirin and 
mirtazapine not removed
Food portions not increased, high 
energy supplements prescribed 
(1080 kJ/day)
Measured in kg/m2, <9.5 kg/m2 is considered Sarcopenic.27
december 2016, adverse event: patient sustained minor elbow wound from injurious fall in facility. Infected wound led to sepsis, resulting in seizure and hospitalisation. Sodium valproate 
added to prescription. Patient restrained and catheterised and subsequently developed UTI and delirium.
February 2017, adverse event: patient experienced injurious fall within facility resulting in several fractured ribs and required hospitalisation. Physical restraints implemented in the 
reclining chair. Following medications added to prescription over 5- month period; risperidone, buprenorphine (patch), oxycodone, paracetamol. Supra- pubic catheter placed. Several UTIs 
reported. Completely immobile and highly sedated.
BIA SMI, bioelectrical impedance skeletal muscle index; BMI, body mass index; BP, blood pressure; HR, heart rate; LDL, low density lipoprotein; MMSE, mini- mental state exam; MNA- SF, Mini- 
nutritional Assessment Short Form; SPPB, short physical performance battery; Sx, symptoms; TC, total cholesterol; UTI, urinary tract infection.
of deprescribing, increased protein–energy intake and robust 
anabolic exercise.
CASE pRESEnTATion
An 87- year- old man diagnosed with mild DLB 1 year prior by 
a geriatrician and living in a residential aged care facility since 
diagnosis was screened for a pilot exercise trial.21 He satisfied 
both the 2005 and 2017 criteria for the diagnosis of probable 
DLB including the onset of dementia prior to motor symptoms 
and the presence of two or more core features: fluctuating 
cognition and alertness, well- formed visual hallucinations and 
spontaneous parkinsonism features.22 23 He resided in a room 
by himself and his wife lived in the community, visiting daily. 
He had a recent history of recurrent falls and had lost 7% of 
his body weight in the 12 months since moving into the facility. 
Medical history included osteoporosis with hip fracture 5 years 
prior, chronic obstructive pulmonary disease (COPD), gout, 
dyslipidaemia, hypertension, macular degeneration, depression 
and a history of excessive alcohol consumption prior to admis-
sion. Medications included mirtazapine, aspirin, perindopril, 
atorvastatin, tiotropium bromide, paracetamol and allopurinol. 
A texture- modified diet had been implemented due to concerns 
surrounding dysphagia and potential aspiration. The patient was 
observed to rapidly deteriorate in health status, precipitated by 
two injurious falls over 9 months while enrolled in a wait- list 
control period for the exercise trial. Evaluations were conducted 
to identify potential aetiologic factors in his rapid functional 
decline.
invESTigATionS
The study geriatrician and exercise physiologist undertook 
external investigations during an extended, 9- month wait- list 
period due to the ill health of the patient prior to intervening. 
Table 1 presents a timeline of relevant investigations and adverse 
events. A key limitation to investigations involved the lack of 
dietary assessment and nutritional biochemistry, as the study 
geriatrician was not the primary physician for the patient and 
therefore was not authorised to order these in his residential aged 
care setting. A compete biochemistry panel would have allowed 
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Figure 1 Contribution to frailty trajectory. Timeline illustrating 
the contributions of various negative and positive factors to the 
development of frailty and rehabilitation within the patient over the 
course of 29 months with inclusion of adverse events. The size of the 
plus/minus images indicates the relative magnitude of the effect on 
patient health at each stage. UTI,urinary tract infection.
and strength through indices such as serum albumin, electro-
lyte abnormalities, vitamin B12 or iron deficiencies, thyroid 
hormone imbalances and diabetes. Physical assessment revealed 
the predominant DLB features in the patient, which were non- 
threatening hallucinations, orthostasis, drooling, mild rigidity in 
all limbs with a full range of motion, ataxia and postural insta-
bility. Notably absent were dystonia, dyskinesia, depression and 
dysphagia.
diFFEREnTiAl diAgnoSiS
The aged care management plan for the patient appeared palli-
ative and reactionary in approach to falls, pain management 
and psychosis, and suggested that the decline in function was 
viewed as an inevitable accompaniment to his DLB. However, 
the external research team elucidated many core, modifiable 
factors potentially contributing to the frailty through their 
investigations.
natural disease course of dlB
DLB is an aggressive form of dementia with a lifespan postdi-
agnosis of 3–8 years.24 The rate of cognitive decline in prospec-
tive studies is two to four points on the Mini- mental State Exam 
(MMSE) every year postdiagnosis.24 The disease is characterised 
by acute fluctuations and a progressive decline in function over 
time, and is not relapsing–remitting in nature. The patient at 
baseline had mild cognitive impairment, was only mildly rigid 
with full range of motion and did not have depression, trou-
bling hallucinations, dystonia or dyskinesia. Poorer prognostic 
outcomes are mainly precipitated in DLB by neuropsychiatric 
symptoms and hospitalisations from falls and bronchopneu-
monia,25 similar to the general ageing cohort. However, this 
patient presented with a much more rapid cognitive deterioration 
of eight points over 9 months. Despite no change to his non- 
threatening hallucinations, the antipsychotic risperidone was 
added to his medication regime, resulting in an acute worsening 
in extrapyramidal symptoms including tardive dyskinesia, trunk 
dystonia and rigidity. The rapid onset of these symptoms suggest 
iatrogenesis/delirium rather than the natural, degenerative 
disease progression.
Sarcopenia
The patient was sarcopenic at baseline, worsening at follow- up 
time points. Both isometric handgrip and appendicular strength 
were below age- matched thresholds at baseline26 and deterio-
rated over the 9- month period in concert with declining physical 
activity levels. Body composition analysis confirmed a skeletal 
muscle mass (SMM) index below the sarcopenia definition of 
<9.5 kg/m2,27 deteriorating from 8.43 to 7.8 kg/m2 in the first 
8 weeks of acute illness/sepsis, associated with a 6.5 kg overall 
weight loss. This equates to an average weekly loss of muscle 
mass of 250 g/week during that period, which is significantly 
higher than estimated in young, healthy bedrest models of muscle 
atrophy of 100–200 g/week,28 and consistent with the literature 
reports of 25% of body weight loss being SMM.11 This muscle 
loss likely continued (although not directly measured) with the 
further 11 kg of weight loss in the subsequent 5 months concom-
itant with restraint use, immobilisation and recurrent infections. 
Additionally, a significant decrease in gait speed, transfer and 
balance function accompanying muscle loss, progressing to 
non- ambulatory, chair/bed- bound status confirmed severe sarco-
penia. Finally, the use of atorvastatin and vitamin D deficiency 
were also potential contributors to muscle weakness throughout 
the early stages of the decline.29
Malnutrition
The patient was at risk of malnutrition at baseline according 
to the Mini- nutritional Assessment (MNA)30 and developed 
severe malnutrition during the follow- up. Anorexia of ageing 
is a contributing factor to be considered, however, the patient 
always reported hunger, not loss of appetite. By contrast, there 
were multiple modifiable factors potentially driving insufficient 
energy intake.31 First, the prescription of anti- cholinergic and/or 
sedating medications (oxycodone, buprenorphine, risperidone, 
sodium valproate, mirtazapine, tiotropium) likely decreased the 
patient’s opportunity to eat and contributed to the dysphagia 
known to be present in DLB32 as well as reduced saliva produc-
tion, impairing mastication and swallowing along with the 
absence of lower teeth. A pureed diet was prescribed due to 
fear of aspiration. Texture- modified diets have been observed to 
significantly reduce the daily energy and protein intake in older 
adults10 as does eating in isolation with minimal social engage-
ment.5 Additionally, there were potentially underlying cachexic 
processes from the recurrent infections, COPD diagnosis as well 
as statin and ACE- inhibitor prescriptions.7 Finally, the patient 
reported feeling hunger between meals and readily ate all food 
provided, which suggests the energy or protein content of food 
provided was not satiating or sufficient. Furthermore, no assess-
ment of caloric intake or calculation of energy requirements for 
maintenance (approximately 30 kcal/kg/day) or weight increase 
(35 kcal/kg/day) or protein needs (1.2 g/kg/day) was conducted 
by the aged care facility despite severe and persistent weight 
loss.33–35
Cognitive impairment and atherosclerotic processes
The patient was eulipidaemic and normotensive, with no history 
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Figure 2 Intervention components.
Figure 3 Patient medication prescription timeline.
disease, and no current alcohol or smoking (ex- smoker—discon-
tinued 10 years prior) suggesting that atherosclerosis was not 
a recent contributing factor to progressive frailty or cognitive 
impairment. Apathy and depression are common predictors of 
malnutrition and cognitive performance in DLB,4 8 36 yet were 
absent in this patient at all assessment points. The high seda-
tive burden of his medication regimen (five drugs with this side 
effect) was likely contributing to his cognitive impairment,6 37 
especially considering the extra- pyramidal side effects observed 
(tardive dyskinesia, rigidity, trunk dystonia). His significantly 
reduced level of alertness and loss of postural control and 
communication ability witnessed just after administration of 
risperidone and sodium valproate was consistent with a drug- 
related delirium. The rapid eight- point decrease in his MMSE 
over a 9- month period, which is a similar decline to that 
reported in postoperative literature,9 38 was likely precipitated 
by recurrent and persistent delirium from multiple episodes of 
infection and malnutrition, in addition to the central nervous 
system side effects of several medications noted above.
Summary
The final diagnosis we provided to the facility staff was an exac-
erbation of underlying frailty due to sarcopenia, malnutrition, 
polypharmacy and isolation/immobility, with all factors poten-
tially treatable with targeted, robust interventions and changes 
in clinical care. All of these factors were inseparably involved in 
the decline (figure 1). For example, sedating drugs reduced the 
ability to eat, exacerbated sarcopenia and impaired strength and 
functional mobility, increasing fall risk further. Thus, without 
a comprehensive approach to all implicated factors, recovery 
would be sub- optimal or impossible.
TREATMEnT
deprescribing
Over the course of observation, deprescribing with ratio-
nale was recommended to the facility doctor at several time 
points (figure 2) to reduce iatrogenic influences of polyphar-
macy based on consensus criteria.39 Primarily, most drugs were 
recommended for removal through lack of indication or being 
prescribed beyond the duration of treatment, which are stand-
alone reasons to deprescribe. Additionally, specific contraindica-
tions included duplicate drug classes, ACE inhibitors with low/
normal BP, anticholinergics in patients with dementia/delirium, 
long- acting with short- acting opioids for breakthrough pain, 
overall increased anticholinergic burden and inappropriate 
antipsychotics use for several categories including prescription 
for Parkinsonian disorders, behavioural symptoms in dementia 
and in patients with falls risk. There was also one indication for 
starting a prescription, namely adding vitamin D for known oste-
oporotic fractures of hip, spine and ribs and low lab value in an 
institutionalised patient.
Exercise and nutrition
The study exercise physiologist commenced intensive anabolic 
exercise, and the facility was instructed to increased energy 
intake from 1080 to 5040 kJ/day through liquid supplements, 




 April 27, 2020 at Jam
es Cook University. Protected by
http://casereports.bmj.com/
BM
J Case Rep: first published as 10.1136/bcr-2019-231336 on 26 April 2020. Downloaded from
 
5Inskip M, et al. BMJ Case Rep 2020;13:e231336. doi:10.1136/bcr-2019-231336
Reminder of important clinical lesson
Figure 4 Frailty measures and outcomes from intervention. Graphs: 
relationship between body weight over time with (top) skeletal muscle 
index, (middle) cognition and (bottom) physical function. Intervention 
occurred between 9 and 11 months indicated in the green zone. 
Indicates no data collection, extrapolated from 29- month value of 
similar body weight. MMSE, mini- mental state examination; SPPB, short 
physical performance battery.
Figure 5 Rapid deconditioning and rehabilitation of patient. (A) 
Patient able to stand without hands at baseline assessment. (B) Weight 
loss of 8 kg and unable to stand without lifter after sepsis and delirium. 
(C) Further loss of 17.5 kg, immobile after rib fracture, deconditioning 
and sedation. (D) Weight gain of 5 kg, patient walking with contact 
guard after intensive rehabilitation for 8 weeks. BL, baseline.
re- evaluating the need for a pureed diet as there was no evidence 
of aspiration. This was done in response to the severe and 
progressive undernutrition present, as evidenced by a weight loss 
of 17.5 kg, body mass index of 23 kg/m2 decreasing to 17.7 kg/m2, 
marked muscle wasting on physical exam, MNA score decreasing 
from 10/14 to 0/14, and complaints of hunger. Falls and infec-
tions are well- known co- morbidities associated with poor nutri-
tional status in nursing home residents and were also present 
in this case. Protein and caloric supplementations significantly 
reduce mortality and complications as well as promoting weight 
change in undernourished patients.40 Exercises were progressed 
in weeks 1–3 and administered in the facility to regain strength, 
standing and walking function to enable transport to the clinical 
gym for weeks 4–8. High- intensity progressive resistance training 
was performed on key muscle groups. All training throughout 
the 8- week period occurred as 3 days/week for 1- hour sessions 
and are described in figure 2.
oUTCoME And Follow-Up
The patient improved significantly following deprescribing 
and had no adverse consequences. A total of nine medications 
were assessed and recommended for immediate removal from 
the prescription across all time points. The prescription at each 
time point is detailed in figure 3. All medications except sodium 
valproate were ultimately removed, and high- energy supple-
ments were prescribed (5040 kJ/day) in addition to his normal 
meal routine. The patient’s wife signed a waiver to allow the 
addition of some solid foods to his daily diet. The exercise 
intervention (figure 2) was tolerated well by the patient, and 
all 24 sessions were completed with no adverse events. Figure 4 
displays key intervention results of the patient prior to, and 
following interventions. Figure 5 illustrates the rapid, clinically 
significant improvement in his overall function and health status, 
which included a transition from being chair- bound to ambula-
tory with contact guarding.
The patient was followed up 18 months after the study contact 
ceased, during which time no specific exercise was provided 
by the facility (2019). He had initially continued to walk with 
his wife’s support until he became too weak to stand with her 
assistance and was again wheelchair- bound. He was unable to 
stand even with assistance and had flexion contractures of both 
knees. He had lost all the weight that had been restored during 
the intervention period and weighed only 56.5 kg (17.5 kg/
m2, malnourished), with severe wasting of all skeletal muscles. 
Superficial lacerations were present on limbs. He was alert and 
conversational and had no extrapyramidal or psychotic symp-
toms, although his MMSE had declined to 12/30, which was 
a similar score to when he was last at this body weight prior 
to intervention. His only regular medications were paracetamol, 
vitamin D and a laxative solution.
Current care plan
Deprescribing has been successfully implemented, and although 
the presence of malnutrition was documented and dietary 
supplements prescribed by the facility, the continued weight 
loss suggests that actual energy and protein intake are far below 
needs. Actual documentation of his nutrient intake is needed 
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patient’s perspective
When my husband began to get worse, I felt like I was losing 
him. He was confused and upset, and his condition was bad. I 
would worry every time I would receive a call from the aged care 
facility, as I feared my husband might have injured himself once 
again. During this time, I felt like his quality of life was very poor. 
I couldn’t talk normally with him and could not take him out for 
a coffee or a meal. I was very scared for his future, he had lost 
that much weight and was always sleeping, and the staff at the 
facility had told me to prepare for the worst.
A few days after his medications were removed, he was 
more awake and his humour and happiness came back. He 
began to know where he was, and it was beautiful to see him 
start doing the exercises to get him stronger and build muscle. 
Soon he was walking and we could get him into my car to drive 
him to the clinic, so he could do even more intense exercise. I 
even started training myself. My husband said that the exercise 
programme and walking again was a ‘wonderful experience’. I 
kept walking him every day after the intervention finished, even 
though the staff was hesitant. We only stopped when he started 
to lose muscle again, which made it harder for me to stand him 
on his own. It would be great to see him able to do the robust 
resistance exercises again as he did in the study, as I think it is 
the only thing that can keep him strong enough to walk. The 
biggest challenge is finding the right facility and professionals 
that know how to train my husband like those in the study.
learning points
 ► This case highlights the concerning disparity between 
recommended optimal care for frailty and the reality of care 
for some patients in residential aged care facilities
 ► The aetiology of frailty in dementia has many significant 
modifiable components that must be differentiated from the 
contributions of normal ageing and underlying disease.
 ► Anabolic interventions consisting of robust progressive 
resistance training, and increased energy and protein intakes 
are the most effective treatments for sarcopenia, malnutrition 
and frailty.
 ► Deprescribing in dementia when appropriate and observing 
patient condition offers an effective way of gauging 
iatrogenic contributions of polypharmacy to frailty, cognitive 
decline, sarcopenia and malnutrition.
 ► Highly clinically meaningful outcomes can be gained 
using resistance training in patients with advanced age, 
neurodegenerative disease and severe sarcopenia, including 
regaining of ambulatory status in previously immobilised, 
chair- restrained patients. However, withdrawal of anabolic 
exercise reverses these gains.
intake relative to his energy and protein needs for weight gain/
anabolism using standard metabolic equations.33
The severe sarcopenia (low strength, SMM and functional 
mobility) he now manifests suggests that without robust anabolic 
exercise, this sarcopenia is insufficiently addressed by the depre-
scribing and nutritional supplementation. It should be noted 
that without anabolic exercise, nutritional supplements reduce 
habitual intake at meals, and thus do not actually augment total 
nutrient intake as anticipated.41 Thus, resistance training is the 
critical missing component needed for treatment of both sarco-
penia and malnutrition.
diSCUSSion
This is the first documented case of intensive progressive resis-
tance training administered in a patient with DLB. The litera-
ture surrounding the effects of exercise is scarce and limited to 
several case reports,42 which evaluate aerobic, neuro- motor or 
functional training in clinically stable individuals. Additionally, 
this case provides a rare, longitudinal insight into the factors 
contributing to the rapid development of frailty in a patient with 
dementia in residential care and the key clinical assessments that 
guided effective rehabilitation.
However, the rapid decline reported in this scenario is likely 
to be a common but poorly documented occurrence in aged care 
facilities due to the high prevalence of risk factors. For instance, 
dementia is present in approximately 60% of all residential care 
patients.43 One- third are sarcopenic,20 one- half are currently, or 
at- risk of malnutrition36 and over 60% are frail.44 Additionally, 
almost one- half of all residents are prescribed at least one poten-
tially inappropriate medication, of which neuroleptics are the 
most common.45
This case highlights the concerning disparity between 
recommended optimal care for frailty and the reality of care 
for some patients in residential aged care facilities. The highest 
cause of accidental death in aged care facilities is falls, and 
as expected, the industry has evolved to prioritise safety and 
falls reduction. However, implementing immobilisation and 
restraints as a strategy to reduce falls further exacerbates the 
process of frailty, which is independently the most significant 
risk factor for falls.46 Furthermore, the healthcare costs for 
frail patients far exceed the cost of non- frail patients, which 
places further strain on service delivery within residential aged 
care facilities.47
Comprehensive geriatric assessment involving deprescribing, 
anabolic resistance training exercise and increased protein–en-
ergy intake are effective methods of mitigating the cycle of 
frailty.17 48 49 Importantly, withdrawal of anabolic interventions 
will likely precipitate a return to the previous level of functional 
decline. Extreme frailty is not a contraindication to compre-
hensive geriatric assessment and robust anabolic interventions. 
Conversely, it is one of the most important reasons to implement 
these treatment strategies.
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